Skip to main content

Table 3 The signal values of GERD-like symptoms of GLP-1-RAs and DPP-4-Is

From: Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database

Class

Drug name

n11

n1+

ROR (95%CI)

IC (95%CI)

GLP-1-RAs

(ALL)

36

429

5.61* (3.95–7.96)

2.17* (1.66–2.67)

 

dulaglutide

1

20

3.08 (0.41–23.04)

0.56 (−1.57–2.70)

 

exenatide

19

122

11.08* (6.75–18.18)

2.70* (2.00–3.41)

 

liraglutide

15

278

3.39* (2.00–5.74)

1.49* (0.74–2.24)

 

lixisenatide

1

12

5.32 (0.69–41.28)

0.71 (− 1.48–2.91)

DPP-4-Is

(ALL)

31

3276

0.54 (0.37–0.77)

-0.81 (− 1.34 – −0.29)

 

alogliptin

1

345

0.17 (0.02–1.20)

− 1.77 (−3.82–0.28)

 

anagliptin

0

72

 

linagliptin

4

332

0.71 (0.26–1.91)

−0.40 (−1.71–0.90)

 

omarigliptin

0

2

 

saxagliptin

0

70

 

sitagliptin

16

1181

0.80 (0.48–1.31)

−0.30 (−1.01–0.41)

 

teneligliptin

0

98

 

trelagliptin

1

19

3.25 (0.43–24.39)

0.58 (−1.56–2.72)

 

vildagliptin

9

1189

0.44 (0.23–0.85)

−1.07 (−2.00 – −0.15)

  1. GERD gastroesophageal reflux disease, GLP-1-RAs glucagon-like peptide-1 receptor agonists, DDP-4-Is dipeptidyl peptidase-4 inhibitors, n 11 the number of target drug induced GERD-like symptoms, n 1+ the number of target drug induced all adverse events, ROR reporting odds ratio, IC information component
  2. * signal detection